Veloxis Pharmaceuticals AS - Strategy, SWOT and Corporate Finance Report

Veloxis Pharmaceuticals AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.

Veloxis Pharmaceuticals A/S (Veloxis) is a specialty pharmaceutical company that identifies, develops and commercializes pharmaceutical drugs in transplantation and adjacent therapies. The company developed ENVARSUS XR (tacrolimus extended-release tablets) for the prophylaxis of organ rejection in kidney transplant patients. ENVARSUS is developed based on the company’s proprietary, patented drug delivery technology, MeltDose, which is designed to enhance the absorption and bioavailability of select orally administered drugs. Veloxis out licensed the commercial rights of Envarsus MENA region, Canada and China. The company sells ENVARSUS XR to wholesalers, specialty pharmacies and other customers. Veloxis is headquartered in Copenhagen, Denmark.

Scope

  • Detailed information on Veloxis Pharmaceuticals AS required for business and competitor intelligence needs
  • A study of the major internal and external factors affecting Veloxis Pharmaceuticals AS in the form of a SWOT analysis
  • An in-depth view of the business model of Veloxis Pharmaceuticals AS including a breakdown and examination of key business segments
  • News about Veloxis Pharmaceuticals AS, such as business expansion, restructuring, and contract wins
  • Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

  • Gain understanding of Veloxis Pharmaceuticals AS and the factors that influence its strategies.
  • Track strategic initiatives of the company and latest corporate news and actions.
  • Assess Veloxis Pharmaceuticals AS as a prospective partner, vendor or supplier.
  • Support sales activities by understanding your customers' businesses better.
  • Stay up to date on Veloxis Pharmaceuticals ASs business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Vivus UK Ltd

Quantum Genomics SA

NeuroSearch A/S

Metkinen Oy

H. Lundbeck AS

Astellas Pharma A/S

Accord Healthcare AB

Vivus UK Ltd

Quantum Genomics SA

NeuroSearch A/S

Metkinen Oy

H. Lundbeck AS

Astellas Pharma A/S

Accord Healthcare AB

Table of Contents

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1 - About the Company 6

Veloxis Pharmaceuticals A/S ...

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1 - About the Company 6

Veloxis Pharmaceuticals A/S - Key Facts 6

Veloxis Pharmaceuticals A/S - Key Employees 7

Veloxis Pharmaceuticals A/S - Key Employee Biographies 8

Veloxis Pharmaceuticals A/S - Major Products and Services 9

Veloxis Pharmaceuticals A/S - History 10

Veloxis Pharmaceuticals A/S - Company Statement 12

Veloxis Pharmaceuticals A/S - Locations And Subsidiaries 13

Head Office 13

Other Locations & Subsidiaries 13

Section 2 – Company Analysis 14

Company Overview 14

Veloxis Pharmaceuticals A/S - Business Description 15

Veloxis Pharmaceuticals A/S - Corporate Strategy 16

Veloxis Pharmaceuticals A/S - SWOT Analysis 17

SWOT Analysis - Overview 17

Veloxis Pharmaceuticals A/S - Strengths 17

Veloxis Pharmaceuticals A/S - Weaknesses 18

Veloxis Pharmaceuticals A/S - Opportunities 19

Veloxis Pharmaceuticals A/S - Threats 20

Veloxis Pharmaceuticals A/S - Key Competitors 21

Section 3 – Company Financial Ratios 22

Financial Ratios - Capital Market Ratios 22

Financial Ratios - Annual Ratios 23

Performance Chart 25

Financial Performance 25

Financial Ratios - Interim Ratios 26

Financial Ratios - Ratio Charts 27

Section 4 – Company’s Lifesciences Financial Deals and Alliances 28

Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28

Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 29

Veloxis Pharmaceuticals A/S, Recent Deals Summary 30

Section 5 – Company’s Recent Developments 31

May 14, 2018: Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2018 31

Apr 13, 2018: Veloxis Pharmaceuticals - Passing of Annual General Meeting 2018 32

Apr 03, 2018: Veloxis Appoints Morten Marott as Chief Financial Officer 33

Feb 27, 2018: Veloxis Pharmaceuticals Releases Annual Report for 2017 34

Feb 14, 2018: Veloxis Secures $60M in Debt Financing 35

Nov 14, 2017: Veloxis Pharmaceuticals Announces Financial Results for the First Nine Months of 2017 36

Sep 20, 2017: Alastair McEwan Steps Down as Chief Operating Officer of Veloxis Pharmaceuticals 37

Sep 13, 2017: Veloxis Pharmaceuticals Appoints Ulf Meier-Kriesche, MD, as Chief Scientific Officer 38

Aug 16, 2017: Veloxis Pharmaceuticals Announces Financial Results for the First Six Months of 2017 39

May 16, 2017: Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2017 40

Section 6 – Appendix 41

Methodology 41

Ratio Definitions 41

About GlobalData 45

Contact Us 45

Disclaimer 45

List of Tables

List of Tables

Veloxis Pharmaceuticals A/S, Key Facts 6

Veloxis Pharmaceuticals A/S, Key Employees 7

Veloxis Pharmaceuticals A/S, Key Employee Biographies 8

Veloxis Pharmaceuticals A/S, ...

List of Tables

Veloxis Pharmaceuticals A/S, Key Facts 6

Veloxis Pharmaceuticals A/S, Key Employees 7

Veloxis Pharmaceuticals A/S, Key Employee Biographies 8

Veloxis Pharmaceuticals A/S, Major Products and Services 9

Veloxis Pharmaceuticals A/S, History 10

Veloxis Pharmaceuticals A/S, Subsidiaries 13

Veloxis Pharmaceuticals A/S, Key Competitors 21

Veloxis Pharmaceuticals A/S, Ratios based on current share price 22

Veloxis Pharmaceuticals A/S, Annual Ratios 23

Veloxis Pharmaceuticals A/S, Annual Ratios (Cont...1) 24

Veloxis Pharmaceuticals A/S, Interim Ratios 26

Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28

Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 29

Veloxis Pharmaceuticals A/S, Recent Deals Summary 30

Currency Codes 41

Capital Market Ratios 41

Equity Ratios 42

Profitability Ratios 42

Cost Ratios 43

Liquidity Ratios 43

Leverage Ratios 44

Efficiency Ratios 44

List of Figures

List of Figures

Veloxis Pharmaceuticals A/S, Performance Chart (2013 - 2017) 25

Veloxis Pharmaceuticals A/S, Ratio Charts 27

Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals ...

List of Figures

Veloxis Pharmaceuticals A/S, Performance Chart (2013 - 2017) 25

Veloxis Pharmaceuticals A/S, Ratio Charts 27

Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28

Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 29

    Pricing

Discounts available for multiple report purchases.

reportstore@marketline.com
+44 (0) 161 359 5817

Saved reports